162 related articles for article (PubMed ID: 7722322)
1. Vaccination routes that fail to elicit protective immunity against Schistosoma mansoni induce the production of TGF-beta, which down-regulates macrophage antiparasitic activity.
Williams ME; Caspar P; Oswald I; Sharma HK; Pankewycz O; Sher A; James SL
J Immunol; 1995 May; 154(9):4693-700. PubMed ID: 7722322
[TBL] [Abstract][Full Text] [Related]
2. Induction of protective immunity against Schistosoma mansoni by a nonliving vaccine. III. Correlation of resistance with induction of activated larvacidal macrophages.
James SL
J Immunol; 1986 May; 136(10):3872-7. PubMed ID: 3084646
[TBL] [Abstract][Full Text] [Related]
3. Calpain is the target antigen of a Th1 clone that transfers protective immunity against Schistosoma mansoni.
Jankovic D; Aslund L; Oswald IP; Caspar P; Champion C; Pearce E; Coligan JE; Strand M; Sher A; James SL
J Immunol; 1996 Jul; 157(2):806-14. PubMed ID: 8752932
[TBL] [Abstract][Full Text] [Related]
4. T-helper type-1-dominated lymph node responses induced in C57BL/6 mice by optimally irradiated cercariae of Schistosoma mansoni are down-regulated after challenge infection.
Pemberton RM; Wilson RA
Immunology; 1995 Feb; 84(2):310-6. PubMed ID: 7751008
[TBL] [Abstract][Full Text] [Related]
5. Elevated expression of Th1 cytokines and nitric oxide synthase in the lungs of vaccinated mice after challenge infection with Schistosoma mansoni.
Wynn TA; Oswald IP; Eltoum IA; Caspar P; Lowenstein CJ; Lewis FA; James SL; Sher A
J Immunol; 1994 Dec; 153(11):5200-9. PubMed ID: 7525727
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor-beta and Th17 responses in resistance to primary murine schistosomiasis mansoni.
Tallima H; Salah M; Guirguis FR; El Ridi R
Cytokine; 2009 Dec; 48(3):239-45. PubMed ID: 19717308
[TBL] [Abstract][Full Text] [Related]
7. [Effects of secretory leukocyte protease inhibitor on the production of some cytokines and nitric oxide by murine peritoneal macrophages in response to lipopolysaccharide stimulation and M. avium complex infection].
Sano C; Shimizu T; Sato K; Ogasawara K; Tomioka H
Kekkaku; 1999 Jul; 74(7):563-70. PubMed ID: 10481411
[TBL] [Abstract][Full Text] [Related]
8. Induction of Th1 cell-mediated protective immunity to Schistosoma mansoni by co-administration of larval antigens and IL-12 as an adjuvant.
Mountford AP; Anderson S; Wilson RA
J Immunol; 1996 Jun; 156(12):4739-45. PubMed ID: 8648120
[TBL] [Abstract][Full Text] [Related]
9. IL-12 enhances vaccine-induced immunity to Schistosoma mansoni in mice and decreases T helper 2 cytokine expression, IgE production, and tissue eosinophilia.
Wynn TA; Jankovic D; Hieny S; Cheever AW; Sher A
J Immunol; 1995 May; 154(9):4701-9. PubMed ID: 7722323
[TBL] [Abstract][Full Text] [Related]
10. IL-10 synergizes with IL-4 and transforming growth factor-beta to inhibit macrophage cytotoxic activity.
Oswald IP; Gazzinelli RT; Sher A; James SL
J Immunol; 1992 Jun; 148(11):3578-82. PubMed ID: 1588047
[TBL] [Abstract][Full Text] [Related]
11. Induction of protective immunity against Schistosoma mansoni by a nonliving vaccine. II. Response of mouse strains with selective immune defects.
James SL; DeBlois LA
J Immunol; 1986 May; 136(10):3864-71. PubMed ID: 3084645
[TBL] [Abstract][Full Text] [Related]
12. Alterations in cytokine production following intraocular injection of soluble protein antigen: impairment in IFN-gamma and induction of TGF-beta and IL-4 production.
Kosiewicz MM; Alard P; Streilein JW
J Immunol; 1998 Nov; 161(10):5382-90. PubMed ID: 9820512
[TBL] [Abstract][Full Text] [Related]
13. Induction of protective immunity against Schistosoma mansoni by a non living vaccine. I. Partial characterization of antigens recognized by antibodies from mice immunized with soluble schistosome extracts.
James SL; Pearce EJ; Sher A
J Immunol; 1985 May; 134(5):3432-8. PubMed ID: 3980998
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Th1- and Th2-associated immune reactivities stimulated by single versus multiple vaccination of mice with irradiated Schistosoma mansoni cercariae.
Caulada-Benedetti Z; al-Zamel F; Sher A; James S
J Immunol; 1991 Mar; 146(5):1655-60. PubMed ID: 1671579
[TBL] [Abstract][Full Text] [Related]
15. Optimal vaccination against Schistosoma mansoni requires the induction of both B cell- and IFN-gamma-dependent effector mechanisms.
Jankovic D; Wynn TA; Kullberg MC; Hieny S; Caspar P; James S; Cheever AW; Sher A
J Immunol; 1999 Jan; 162(1):345-51. PubMed ID: 9886405
[TBL] [Abstract][Full Text] [Related]
16. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
17. Schistosoma mansoni: protective immunity in IL-4-deficient mice.
King CL; Malhotra I; Jia X
Exp Parasitol; 1996 Nov; 84(2):245-52. PubMed ID: 8932774
[TBL] [Abstract][Full Text] [Related]
18. Modulation of macrophage activation and resistance by suppressor T lymphocytes in chronic murine Schistosoma mansoni infection.
Olds GR; Ellner JJ
J Immunol; 1984 Nov; 133(5):2720-4. PubMed ID: 6237154
[TBL] [Abstract][Full Text] [Related]
19. Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis.
Elias D; Akuffo H; Pawlowski A; Haile M; Schön T; Britton S
Vaccine; 2005 Feb; 23(11):1326-34. PubMed ID: 15661380
[TBL] [Abstract][Full Text] [Related]
20. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages.
Gazzinelli RT; Oswald IP; James SL; Sher A
J Immunol; 1992 Mar; 148(6):1792-6. PubMed ID: 1541819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
